DXN HOLDINGS BHD.
KLSE (MYR): DXN (5318)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.595
Today's Change
-0.005 (0.83%)
Day's Change
0.595 - 0.60
Trading Volume
302,400
News and Blogs
Discussions
Be the first to like this. Showing 50 of 437 comments
Monday is a public Holiday.no trading and a long weekend break. Most counters sideway
2024-05-31 15:54
Ganoderma, DXN's main product, is the cause of basal stem rot, a serious disease in oil palm trees. See http://sawitsecure.mpob.gov.my/ganoderma-basal-stem-rot/ and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571826/
According to Section 7.28.1 of the Prospectus, DXN is facing non-compliances with land use and express conditions on land titles in Kedah and has shut down at least some of its Ganoderma cultivation and processing facilities.
I wonder about the extent to which the fear of Ganoderma in the plantation industry, perhaps we may call it Ganophobia, affects the current share price and future share price prospects of DXN.
2024-06-17 15:19
going to touch 0.60 again
take break even profit now and move on to better valuation company
2 months ago
last comments to share on this counter:
1. if you are looking for long term investment for good dividend yield counter, you may consider to wait and collect at 0.60-0.62 (currently operators are pressing down the share price)
2. if you are looking for appreciation on share price, you may consider OTHER counters (DXN operators are keen on maintaining the share price below 0.65)
3. LARGE quantity of shares issued, many trust funds involved, share price hardly move (refer to MYEG/DNEX/DSONIC historical movement)
😎 good luck!
2 months ago
Ya.. unless the profit can make rm80m per quarter. Then,the price will stand at least rm0.70.
2 months ago
"In addition to establishing production facilities in Bangladesh and Nepal, we are expanding into the promising Brazilian market. With a population of 215 million and a gross domestic product (“GDP”) of US$1.9 trillion, Brazil's market size exceeds that of Peru, Bolivia, and Mexico combined, the top three (3) markets in our existing Latin American region. Given the proximity to our existing market and cultural similarities, we are confident in our ability to grow in Brazil."
I think they will achieve much more than RM80m per quarter soon.
2 months ago
If can rm80, means dividen sure have 0.01 cent per quarter. So,at least the price should stand rm0.70. Should b no wrong gua.. 🤔🤔
2 months ago
Posted by gsooi100 > 15 hours ago | Report Abuse
should be rm 0.016 to be exact.
If can rm80, means dividen sure have 0.01 cent per quarter. So,at least the price should stand rm0.70. Should b no wrong gua.. 🤔🤔
2 months ago
Yes, it’s very likely that it’s 1 cent or more per quarter this year. This is slightly more than a 6% dividend yield at the current price. Coupled with the growing total addressable market, it’s definitely worth holding for the long term.
2 months ago
profit 80mil is a sure thing. But the market seem unwilling to give it a fair price (fair PE). Nowadays the hot topic is DATA CENTRE. If the company takes any action related to the data center at this time, it will definitely attract market attention. LOL
2 months ago
Yes. DC is the buzz word. Market looking positively at DC related stocks. Others relegated to side show
2 months ago
Buy, dividend ~6%
DXN Holdings 1Q net profit up 10.26%, targets market presence in Zambia, Ghana
1 week ago
Post-briefing update
Sales momentum in the majority of DXN’s operating regions have performed well in 1QFY25 but the surge in DXN’s core raw material costs will eventually weigh on group margins as product price adjustments may not fully offset higher production costs. We lower our FY25E-FY27E earnings estimate by 5%-8%. Rolling forward valuations to CY25E, our TP is lowered to MYR0.85 based on an unchanged 11x PER. Maintain BUY.
1 week ago
DXN Holdings Berhad is a Malaysian company that primarily operates in the health and wellness sector. It is known for its production of dietary supplements, food and beverages, personal care products, and household items, with a focus on Ganoderma-based products.
In terms of potential, DXN Holdings has several factors in its favor:
1. **Global Reach**: DXN operates in over 180 countries with a large network of independent distributors. This wide global footprint provides a strong base for growth, especially in emerging markets where health and wellness trends are increasing.
2. **Growing Health and Wellness Market**: The global demand for supplements, particularly those promoting natural health benefits, is on the rise. DXN's core product offerings align with consumer trends favoring organic and herbal supplements.
3. **Multi-level Marketing Model**: DXN uses a direct selling approach through a multi-level marketing (MLM) model. While MLM has risks and is highly regulated, DXN has sustained a large base of distributors, which supports consistent revenue generation.
4. **Product Diversification**: Beyond supplements, DXN has diversified into other product categories like food, beverages, cosmetics, and personal care. This reduces reliance on any single product and opens opportunities in various sectors.
5. **Sustainability Focus**: DXN’s focus on natural and organic products positions it well in markets that value sustainability and eco-friendly consumption.
Overall, DXN’s strong brand, global presence, and product diversification offer significant growth potential, particularly if it capitalizes on the increasing demand for wellness products.
1 week ago
DXN Holdings Berhad was founded by **Datuk Dr. Lim Siow Jin** in 1993. He is a renowned figure in the wellness industry, especially for his pioneering work with **Ganoderma**, a type of mushroom that is believed to have various health benefits. Dr. Lim's background in holistic health and his passion for natural remedies drove him to establish DXN, focusing on products that promote overall wellness.
Dr. Lim is also well-regarded for his vision of combining the principles of traditional medicine with modern scientific research, particularly in the cultivation and commercialization of Ganoderma. Under his leadership, DXN has grown into a global network, with a presence in over 180 countries, making it one of the prominent names in the direct-selling wellness industry.
His leadership and vision continue to play a significant role in DXN's success and global expansion.
1 week ago
Datuk Dr. Lim Siow Jin, the founder of DXN Holdings, holds a degree in **Engineering** from the **Indian Institute of Technology (IIT), Bombay**. Despite his engineering background, he became deeply interested in traditional medicine, particularly in the health benefits of **Ganoderma** (also known as Lingzhi or Reishi mushrooms), which led him to establish DXN.
Dr. Lim also pursued further studies and research in holistic health and traditional herbal medicine, which played a crucial role in the development of DXN's products. His scientific approach, combined with a passion for natural wellness, has been a key factor in DXN's success in promoting Ganoderma-based health solutions globally.
1 week ago
DXN, a Malaysian-based company, is a global network marketing (MLM) enterprise primarily known for its cultivation, manufacture, and distribution of health and wellness products. Here are some key reasons why DXN might be of interest:
1. **Ganoderma Expertise**: DXN is renowned for its use of **Ganoderma** (a type of mushroom known for its medicinal properties) in its health products. It’s a pioneer in cultivating and marketing this product, which is central to their offerings, particularly in supplements, teas, coffees, and skincare.
2. **Global Reach**: DXN operates in over 180 countries and has a large distributor base. Its global footprint has made it one of the largest MLM companies in Asia, and it has expanded rapidly in regions like Latin America, Africa, and the Middle East.
3. **Network Marketing Model**: As an MLM company, DXN provides opportunities for people to become distributors and earn income through sales and recruitment. This business model has attracted a wide range of individuals looking for entrepreneurial opportunities, especially in developing countries.
4. **Health and Wellness Focus**: DXN’s products cater to the growing global trend of health-conscious consumers, focusing on herbal-based supplements, organic products, and natural remedies. This sector has seen a steady rise, making DXN's offerings more relevant.
5. **Vertical Integration**: DXN controls the entire production process, from farming to manufacturing to distribution. This vertical integration ensures product quality and gives the company better control over costs and supply chains.
6. **Stock Market Listing**: DXN went public and is listed on the Malaysian stock exchange (Bursa Malaysia). It is a point of interest for investors due to its global reach and profitability.
7. **Sustainability & Agriculture**: DXN has been involved in sustainable agricultural practices, especially in the cultivation of Ganoderma, and they emphasize organic farming in their production process.
8. **Resilience in the Market**: The company has maintained steady growth even during challenging economic periods due to its global reach, diverse product range, and growing health-conscious customer base.
These factors contribute to why DXN is often discussed in business, wellness, and investment circles.
1 week ago
Last Price
0.615
Avg Target Price
0.89
Upside/Downside
+0.275 (44.72%)
https://klse.i3investor.com/web/stock/analysis-price-target/5318
1 week ago
very low-profile money-making company, will steady dividend worth while to invest.
1 week ago
just grab from contra players hehe... buy cheaply from margin players... once in a lifetime yah hehe
1 week ago
Direct deal
History
Date Price Change Dir-Volume Day Volume Dir-Value Day Value Avg Price % of Total Share Remarks
15/01/2024 00:00:00 0.6900 -0.0050 36.200m 36.200m 24.978m 24.978m 0.6900 0.7262 -
09/01/2024 00:00:00 0.6950 -0.0050 35.900m 35.900m 24.951m 24.951m 0.6950 0.7202 -
07/08/2023 00:00:00 0.7000 -0.0250 65,790 65,790 46,053 46,053 0.7000 0.0013 -
23/06/2023 00:00:00 0.7000 0.0400 1.000m 1.000m 700,000 700,000 0.7000 0.0201 -
19/05/2023 00:00:00 0.7350 0.0350 1.500m 1.500m 1.103m 1.103m 0.7350 0.0301 -
Summary from 19/05/2023 to 15/01/2024
Highest Price 0.7350 First Occurred on 19/05/2023
Lowest Price 0.6900 First Occurred on 15/01/2024
Highest Volume 36.200m First Occurred on 15/01/2024
1 week ago
DXN did very well in:
Broadening the Products/Markets The future survival and success of a Company hinges on its products and markets.
Under today's highly competitive business environment, there is no guarantee that a
company possessing a very successful product in a very lucrative market will continue to
enjoy such success. Competitors will always try to introduce competing or alternative
products with enhanced performance at greatly reduced price (products and market
strategy). To broaden the product/market base. For example, several successful products
operating in many markets is actually building a strong defence invulnerable to attack.
Building Up Resilience to Recessionary Conditions To build up its resilience against the recessionary pressure. For example, a Company with
a proactive management can expect and sense the approaching of a recession, and work
out strategies in terms of its product/market mix well in advance to reduce the adverse
impact of recession. Moreover, the management may also take some precautionary
measures to make the Company lean, in a stronger position to face the downturn.
5 days ago
All in...
Maybank's target price for DXN Holdings Berhad at 85 sen likely reflects an in-depth analysis of the company's financials, market position, and industry trends. Let’s dive into the exciting details behind this target price!
### **1. **Financial Performance:**
- **Revenue and Profit Growth**: DXN’s recent financial reports might show robust revenue and profit growth, especially in the direct selling industry. Analysts like Maybank would closely evaluate these figures to project future earnings.
- **Earnings Per Share (EPS)**: A strong EPS growth trend could be a key factor in setting the target price. If DXN is delivering impressive EPS figures, it would positively influence Maybank’s valuation.
### **2. **Market Position and Competitive Advantage:**
- **Strong Brand Presence**: DXN, known for its direct selling of health and wellness products, has established a strong brand presence. This competitive advantage can lead to higher market share and better financial performance.
- **Product Line and Innovation**: The company’s diverse and innovative product line, including its flagship Ganoderma-based products, could be contributing to its growth. If DXN is seen as a leader in product innovation, it enhances its investment appeal.
### **3. **Industry Trends:**
- **Growth in Health & Wellness**: The health and wellness industry is experiencing significant growth. If DXN is well-positioned to capitalize on this trend, it could drive higher revenues and profits.
- **Direct Selling Dynamics**: The direct selling model can be highly profitable with lower overhead costs. Analysts might view DXN’s efficiency in this model as a positive factor for future performance.
### **4. **Valuation Metrics:**
- **Discounted Cash Flow (DCF) Analysis**: Maybank might use DCF analysis to estimate the present value of DXN’s future cash flows. A target price of 85 sen could be derived from this valuation method, reflecting the company’s potential to generate future cash flow.
- **Price-to-Earnings (P/E) Ratio**: Comparing DXN’s P/E ratio with industry peers might show it is undervalued or fairly valued at 85 sen. This metric helps analysts gauge whether the stock price aligns with earnings expectations.
### **5. **Market Sentiment and External Factors:**
- **Regulatory Environment**: Positive or stable regulatory conditions for direct selling companies in Malaysia can support a higher target price.
- **Economic Conditions**: Favorable economic conditions and consumer spending trends in Malaysia and other markets where DXN operates could boost its stock price expectations.
### **6. **Strategic Initiatives and Expansion Plans:**
- **New Markets and Products**: DXN’s plans to enter new markets or launch new products can create excitement about its growth prospects. If Maybank sees these initiatives as promising, it could positively impact the target price.
- **Partnerships and Alliances**: Strategic partnerships or alliances that enhance DXN’s market position could be factored into the target price.
### **Excitement Behind the Target Price!**
Imagine DXN as a dynamic company riding the wave of booming health and wellness trends. With a solid financial performance, a winning direct selling model, and exciting product innovations, DXN is like a rocket on the launch pad, ready to soar to new heights. Maybank’s target price of 85 sen reflects their confidence in DXN’s potential to achieve great things and deliver solid returns for investors!
So, if you’re watching DXN, think of it as a thrilling opportunity in a high-growth sector, with plenty of excitement on the horizon! 🚀📈
5 days ago
buy more
DATUK LIM SIOW JIN 09-Jan-2024 Others 80,000,000 0.625
DATUK LIM SIOW JIN 30-Nov-2023 Acquired 345,000 0.651
DATUK LIM SIOW JIN 29-Nov-2023 Acquired 219,600 0.660
DATUK LIM SIOW JIN 28-Nov-2023 Acquired 132,100 0.666
DATUK LIM SIOW JIN 27-Nov-2023 Acquired 98,000 0.663
DATUK LIM SIOW JIN 24-Nov-2023 Acquired 292,300 0.668
DATUK LIM SIOW JIN 23-Nov-2023 Acquired 91,000 0.672
DATUK LIM SIOW JIN 22-Nov-2023 Acquired 133,600 0.659
DATUK LIM SIOW JIN 22-Sep-2023 Acquired 769,100 0.689
DATUK LIM SIOW JIN 21-Sep-2023 Acquired 169,700 0.690
DATUK LIM SIOW JIN 18-Sep-2023 Acquired 115,000 0.699
DATUK LIM SIOW JIN 15-Sep-2023 Acquired 190,600 0.700
DATUK LIM SIOW JIN 14-Sep-2023 Acquired 90,000 0.704
DATUK LIM SIOW JIN 13-Sep-2023 Acquired 684,600 0.699
DATUK LIM SIOW JIN 12-Sep-2023 Acquired 1,863,900 0.694
DATUK LIM SIOW JIN 11-Sep-2023 Acquired 60,000 0.685
MISS ONG HUEY MIN 07-Sep-2023 Acquired 20,000 0.705
MISS ONG HUEY MIN 06-Sep-2023 Acquired 25,000 0.700
MISS ONG HUEY MIN 05-Sep-2023 Acquired 25,000 0.695
MISS ONG HUEY MIN 30-May-2023 Acquired 20,000 0.650
MISS ONG HUEY MIN 29-May-2023 Acquired 10,000 0.655
MISS ONG HUEY MIN 26-May-2023 Acquired 20,000 0.645
MR TEOH HANG CHING 18-May-2023 Others 830,000 0.700
MR TEOH HANG CHING 18-May-2023 Others 39,000 0.700
MR TEOH HANG CHING 18-May-2023 Others 36,000
4 days ago
share buyback, anytime? hehe
From To Type No. of Shares Min Price Max Price
28-Feb-2024 28-Feb-2024 Buyback 1,694,100 0.630 0.630
27-Feb-2024 27-Feb-2024 Buyback 2,242,600 0.630 0.630
26-Feb-2024 26-Feb-2024 Buyback 4,437,800 0.630 0.635
23-Feb-2024 23-Feb-2024 Buyback 1,660,000 0.635 0.640
22-Feb-2024 22-Feb-2024 Buyback 746,800 0.640 0.640
22-Feb-2024 28-Feb-2024 Buyback 10,781,300 0.630 0.640
02-Nov-2023 02-Nov-2023 Buyback 30,000 0.665 0.675
01-Nov-2023 01-Nov-2023 Buyback 200,000 0.660 0.665
31-Oct-2023 31-Oct-2023 Buyback 189,000 0.655 0.675
30-Oct-2023 30-Oct-2023 Buyback 670,200 0.660 0.680
27-Oct-2023 27-Oct-2023 Buyback 190,000 0.670 0.685
26-Oct-2023 26-Oct-2023 Buyback 178,000 0.660 0.675
26-Oct-2023 02-Nov-2023 Buyback 1,457,200 0.655 0.685
4 days ago
DXN's shares appear to be undervalued for several reasons. First, its reliance on the multi-level marketing (MLM) model, while profitable, carries a higher level of regulatory risk and market perception challenges. MLMs are often viewed with skepticism, which can deter some investors from the stock. Additionally, despite its global presence and product diversification in wellness and organic products, the company may face pricing pressure and competition in the rapidly evolving health industry.
The stock's performance also reflects the broader sentiment towards companies like DXN that cater to niche health markets. Although the company is profitable, the share price does not yet reflect its full potential, perhaps due to market apprehension about its MLM structure and concerns regarding growth scalability. Moreover, as of recent data, the stock was trading at 0.615, well below the target price of 0.89, indicating a potential upside of over 44%, suggesting the stock might be undervalued by the market.
4 days ago
History tends to repeat itself 😃
DXN Holdings Bhd (KL:DXN) is set to see an uptrend reversal after bouncing off the 21-day simple moving average line and testing the 66 sen immediate resistance level on Tuesday.
In a trading stocks note on Wednesday, the research house said that if a breakout occurs above this level, bullish momentum may propel the stock towards the 72 sen resistance, and then towards the next resistance level at 77 sen.
3 days ago
Post-briefing update
Sales momentum in the majority of DXN’s operating regions have performed well in 1QFY25 but the surge in DXN’s core raw material costs will eventually weigh on group margins as product price adjustments may not fully offset higher production costs. We lower our FY25E-FY27E earnings estimate by 5%-8%. Rolling forward valuations to CY25E, our TP is lowered to MYR0.85 based on an unchanged 11x PER. Maintain BUY
Source: Maybank
4 hours ago
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-09-17 11:50:00
EMA 5
10 Mins
SELL
2024-09-17 11:10:00
EMA 5
10 Mins
BUY
2024-09-17 10:20:00
EMA 5
10 Mins
SELL
2024-09-17 10:10:00
EMA 5
10 Mins
BUY
2024-09-17 09:30:00
ADX
30 Mins
SELL
Apps
Top Articles
1
3
4
5
Good Articles to Share
6
Good Articles to Share
Putin orders Russian army to grow by 180,000 soldiers to become 1.5 million-strong
7
Good Articles to Share
India gets US$386b funding for renewables target; Reliance, Adani pledge commitments
8
Good Articles to Share
Central Europe factories and retailers shut in flood-hit areas
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
varans16
still holding very well compared to last trading patent
2024-05-31 09:52